Our story starts with a core belief: the key to effective cell therapy is the mastery of the identity, fate and function of cells to create living medicines.
We have assembled a world-class team, including some of the foremost scientific leaders in the fields of oncology and adoptive cell therapy (ACT).
We are applying Gen-R and Epi-R, our proprietary genetic and epigenetic reprogramming technologies, to overcome two major barriers to successful ACT – T cell exhaustion and lack of durable stemness.
We are developing a multi-modality product pipeline. Each of our programs provides opportunities to expand into additional indications beyond those initially targeted.
Lyell Immunopharma Announces Completion of LyFE Manufacturing Center
Join a team of pioneers courageously striving for ambitious goals: cell therapies that eradicate solid tumors. Let’s do it together.